Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
暂无分享,去创建一个
[1] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[2] G. Faulkner,et al. Pharmacologic and Nonpharmacologic Strategies for Weight Gain and Metabolic Disturbance in Patients Treated with Antipsychotic Medications , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[3] J. Lieberman,et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III , 2005, Schizophrenia Research.
[4] D. Goff,et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. , 2005, The Journal of clinical psychiatry.
[5] J. Newcomer. Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.
[6] T. Suppes,et al. Challenges in the management of bipolar depression. , 2005, The Journal of clinical psychiatry.
[7] S. Laurent,et al. Arterial Stiffness and Stroke in Hypertension , 2005, CNS drugs.
[8] C. Koro,et al. The effects of antipsychotic therapy on serum lipids: a comprehensive review , 2004, Schizophrenia Research.
[9] H. Lane,et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. , 2004, The Journal of clinical psychiatry.
[10] J. Newcomer,et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. , 2004, The Journal of clinical psychiatry.
[11] R. Dufresne,et al. Olanzapine increases weight and serum triglyceride levels. , 1999, The Journal of clinical psychiatry.